Public health response following an iGAS outbreak in a residential aged care facility in Queensland

Jai C Van Zeeland, Heshani Rupasinghe, Megan K Young

# Abstract

During an 18-day period, beginning in April 2020, three residents with invasive group A streptococcal infections (iGAS) were reported at a single residential aged care facility (RACF) in Brisbane’s northern geographical region. All three cases were hospitalised with severe illness; two of the cases died as a result of the illness. The Metro North Public Health Unit (PHU) led the public health investigation and response, targeting infection control measures and offering chemoprophylaxis to all 142 staff and 119 residents at the facility. The outbreak was declared over in June, after 30 days of no new cases. Isolates from all three cases were shown to have identical strain typing, emm89. The benefits and challenges of implementing mass chemoprophylaxis in this setting are discussed.

Keywords: Group A; mass chemoprophylaxis; invasive; outbreak; streptococcal disease; residential facility; aged care

# Introduction

Group A Streptococcus pyogenes (GAS) colonises the throat, skin and anogenital tract. In a vulnerable host, GAS can cause localised disease like pharyngitis and impetigo but it can also invade normally sterile sites and cause life-threatening invasive group A streptococcus (iGAS) infection. GAS is transmissible from person to person via respiratory droplets or by direct contact with carriers who may be asymptomatic. 1 Household, institutional and childcare contacts of iGAS cases have an increased risk of iGAS. 2 The overall mortality of iGAS in Australia is 7%; 1 however, iGAS outbreaks in residential aged care facilities (RACFs) are associated with a significantly higher case fatality rate of 25%-60%.3

Approaches to iGAS case and outbreak management vary widely internationally, and within different jurisdictions within Australia. In Queensland, probable and confirmed cases of iGAS are notifiable under the Public Health Act 2005. 4 The incidence of iGAS notifications in Queensland between 2006 and 2015 was 4.5 per 100,000 population per year. 1 Public health interventions aim to prevent onward transmission by ensuring case isolation and appropriate antibiotic treatment and by identifying and advising close contacts who may be at greater risk of acquiring invasive disease. Chemoprophylaxis for close contacts of iGAS infection, to eliminate nasopharyngeal carriage and transmission, remains controversial as reflected in variations in guideline recommendations. 2 The Queensland Health Guidelines advise chemoprophylaxis for mother-baby pairs in the neonatal period and in a confirmed iGAS outbreak. There is currently no vaccine for GAS.

The Queensland Health guidance definition of iGAS outbreaks is outlined in Box 1. A suspected outbreak becomes a confirmed outbreak if the cases are matched through identical molecular typing. Confirming molecular typing prior to chemoprophylaxis has rationale based around the diversity of strains of iGAS, the varying evidence of the effectiveness of mass chemoprophylaxis, the potential complications of chemoprophylaxis and the amount of logistical work required to coordinate such a public health response.

Box 1: Queensland Health guidance for public health units: definition of iGAS outbreaks 1

**Suspected iGAS outbreak:** two or more cases of invasive Group A Streptococcal disease that are epidemiologically linked a (particularly aged care, childcare, hospitals or maternity wards) that occur within a 3 month period.

**Confirmed iGAS outbreak**: two or more cases of invasive Group A Streptococcal disease that are epidemiologically linked a (particularly aged care, childcare, hospitals or maternity wards) that occur within a 3 month period and are identical on molecular typing.

a An epidemiological link exists where cases occur in a physical or geographical context and a plausible mode of transmission accounts for infection spreading between people, AND when one person is likely to have been infectious AND at least one person has an illness which starts within the incubation period after contact with the infectious person.

GAS is typically genotyped using the M protein gene (emm). Worldwide, over 240 different emm types have been identified, those responsible for the majority of invasive disease cases can be reduced to just six, including emm89.5

Although chemoprophylaxis is advised in a confirmed iGAS outbreak in Queensland, there is emphasis in the guidelines that outbreak prevention and management should focus on enhanced surveillance for further cases in addition to addressing environmental contamination and serious breaches in infection control. Chemoprophylaxis is not considered to be a substitute for good infection control.1


In April 2020, multiple residents with iGAS were notified from a single RACF to a large metropolitan public health unit (PHU) in Brisbane’s northern geographical region. Here we describe the progress of the PHU response which ultimately culminated in the establishment of a confirmed outbreak and administration of mass chemoprophylaxis to all 142 staff and 119 residents across six wings. The benefits and challenges of implementing mass chemoprophylaxis in this large institutional setting are discussed to inform future practice. Ethics approval was not required as outbreak identification and management are part of PHU core business and undertaken within the auspices of the Queensland Public Health Act 2005. The facility provided written consent for publication.

# Outbreak description and public health response

Three cases of iGAS were identified and notified over the course of the outbreak (Figure 1). From a clinical perspective, all three cases had multiple medical co-morbidities and blood cultures collected on admission for all three cases became positive for GAS within 5-10 hours of incubation. Case 1 recovered and was discharged after a two-day admission while cases 2 and 3 died as inpatients within 1–4 days of admission.

The PHU was notified of each of the laboratory results electronically via the Notifiable Conditions System (NoCS) within 24–48 hours of the positive GAS results. After notification of the first case, the PHU contacted the RACF manager to risk-assess for further potential cases and to ensure that appropriate infection control procedures were in place. No further cases were identified and there were no significant concerns regarding any other staff or residents with symptoms suggestive of local or invasive GAS. The RACF facilitated GAS-specific education for their staff; environmental cleaning was undertaken by an external provider; and nurses were re-educated on hand hygiene and wound care techniques. They were advised to maintain heightened vigilance of signs and symptoms of GAS and iGAS in other staff and residents for the subsequent 30 days.

**Figure 1: Outbreak timeline**

****

Following notification of Case 2, the PHU contacted the RACF to gather further information and sought to establish the possibility of an outbreak. Case 2 was in the same wing of the facility as Case 1, along with 20 other residents, suggesting an epidemiological link. Following the Queensland Health Guidance for Public Health Units definition for outbreaks (Box 1), a suspected outbreak was declared. An outbreak management team (OMT) led by the RACF was formed and convened daily throughout the outbreak. Cohorting of all staff in the affected wing was recommended and communal activities were ceased. Chemoprophylaxis was not advised at this point; however, it was being considered if the molecular typing showed a matching strain.

The PHU noted that Case 3 resided in a separate wing of the facility and had no direct interaction with the previous two cases. Breaches in infection control measures, suboptimal hand hygiene and wound care techniques, in addition to staff movement across the facility, were considered as possible means of ongoing transmission. The RACF OMT identified 18 residents with wounds actively being managed by nursing staff and facilitated swabs from all wounds. Nil residents or staff with pharyngitis were identified. Screening throat swabs were not collected from staff or residents.

Without strain typing results, the outbreak was still defined as ‘suspected’ upon notification of Case 3 as per the Queensland Health Guidance. However, the PHU recommended that all staff and residents, irrespective of which area or wing they worked or resided, be offered antibiotic chemoprophylaxis with antibiotic choice and dose as detailed in Table 1. Considerable thought was given before recommending mass chemoprophylaxis. The likelihood that the outbreak would be ‘confirmed’ was felt to be high, given the cross-facility involvement despite increased infection control measures already in place. It was acknowledged that Queensland Health guidelines recommend that all staff and residents commence antibiotics simultaneously 1 and that there would be logistical difficulties and potential harms from unnecessary or ill-coordinated antibiotic prophylaxis. Consideration was also given to the number, and level of engagement, of general practitioners (GPs) with the RACF, and to the RACF’s engagement and willingness to participate. The aim of mass chemoprophylaxis was to eliminate carriage in the potential source(s), thereby interrupting any further transmission within the facility.

**Table 1: Recommended chemoprophylaxis for iGAS contacts 1**

|  |  |  |
| --- | --- | --- |
| Antibiotic | Dose | Indications |
| Phenoxymethylpenicillin | Adult: 500 mg orally, 12-hourly for 10 days Child: 15 mg/kg up to 500 mg orally, 12-hourly for 10 days | No hypersensitivity to penicillins |
| Benzathine penicillin | Adult: 900 mg IM as a single dose Child (single dose): 3 to 6 kg: 225 mg IM 6 to 10 kg: 337.5 mg IM 10 to 15 kg: 450 mg IM 15 to 20 kg: 675 mg IM 20 kg or more: 900 mg IM | No hypersensitivity to penicillins Adherence to oral medication a concern Oral therapy is not tolerated NB: Dose may be difficult to obtain and administration may be challenging |
| Cephalexin | Adult: 1 g orally, 12-hourly for 10 days Child: 25 mg/kg up to 1 g orally, 12-hourly for 10 days | Mild penicillin intolerance No immediate hypersensitivity to penicillin |
| Azithromycin | Adult: 500 mg orally, daily for 5 days Child: 12 mg/kg orally, daily for 5 days | Immediate hypersensitivity to penicillin Organism is sensitive to erythromycin |
| Clindamycin | Adult: 300 mg orally, 12-hourly for 10 days | Immediate hypersensitivity to penicillin Organism is not sensitive to erythromycin Organism is sensitive to clindamycin |

The RACF agreed with advice to proceed with mass chemoprophylaxis. The PHU helped to facilitate the process by speaking with the residents’ GPs directly, as well as by providing written advice to distribute to all residents and staff. It was emphasised in communications that the antibiotics were only one part of controlling the transmission of the bacteria, and that ongoing hygiene measures were also essential. A meeting was held between the PHU, the GPs and the RACF to discuss timing of mass prophylaxis to ensure a coordinated approach. The local pharmacy was also an important stakeholder and confirmed availability of the antibiotics. Prophylaxis commenced four days after the onset of Case 3 and 22 days into the suspected outbreak. To provide further support to the RACF, two clinical staff from the PHU met with the RACF manager and quality control lead on site after the onset of Case 3. The visit was helpful in determining the overall layout and staff movements at the RACF and reinforced the decision that the benefits of mass chemoprophylaxis outweighed the risks, as it became clear that effective and ongoing cohorting of both staff and residents would be difficult to achieve.

In total, 99% of staff (n = 140/142) and 97% of residents (n = 115/119) completed their antibiotic course. Logistically, mass chemoprophylaxis proved to be challenging due to the significant number of staff and residents, and the need to tailor antibiotic prescribing given contra-indications in the context of residents with complex medical needs. The cooperation and engagement of GPs assisted greatly in overcoming these difficulties. Another challenging aspect was that, at various times, some staff members, residents and family members of residents expressed concerns about taking the antibiotics. Clear, concise and consistent communication from the PHU and RACF, addressing their concerns, were able to alleviate these fears, resulting in the excellent overall uptake. No antibiotic-related adverse events were reported to the PHU.

Approximately 30 days after the notification of Case 1, it was confirmed that all three cases had isolates that were molecular type emm89. Following Queensland Health guidelines, the outbreak classification was changed from suspected to confirmed. Furthermore, two wound swabs were also positive for GAS, and were also confirmed to be strain type emm89. Both of these residents lived in the same wing as Cases 1 and 2. The RACF were informed of the results although this did not have any impact on public health recommendations. The outbreak was declared over 30 days after the onset of Case 3 when no further suspect or confirmed cases had arisen. No further iGAS cases at the RACF had been notified at the time of this report, more than 12 months later.

# Discussion

The management of the confirmed iGAS outbreak in an institutional RACF setting included mass chemoprophylaxis after careful consideration of the feasibility, risks and benefits of such an intervention. However, central and foremost to the control of the outbreak was effective communication and collaboration between the PHU and RACF staff, residents and families, and GPs. Equally, outbreak management success was felt largely due to detailed attention to, and reaffirming the importance of, infection control. One of the challenges of introducing mass chemoprophylaxis was felt to be that it could easily be misinterpreted by the recipients as being superior to, or used in lieu of, infection control.

Basic infection control principles, which might be considered the mainstay approach to iGAS outbreak control, are universally accepted as essential to both contain and prevent outbreaks. 6 Primarily, this encompasses frequent and rigorous hand washing with soap and water or an alcohol based sanitiser, and accessibility to hand washing facilities. Good wound care techniques should also be targeted, as it is well established that receiving skin and wound care is associated with increased risk of local and invasive GAS infection. 7 Limited data support the presence of GAS on environmental surfaces including carpet, upholstery fabrics and curtains as a contributing factor to transmission, and furthermore, that this contamination is only eliminated once enhanced environmental cleaning is implemented. 8 In six reports of iGAS outbreaks in the literature, suboptimal infection control practices were identified as the major contributing factor in all except one. 3,9–12 Commonly mentioned interventions included hand hygiene; identifying breaches in wound care and improving staff wound care technique; and environmental cleaning. Respiratory droplet precautions were perhaps a notable omission, not mentioned as an iGAS infection control intervention in any of the sighted reports.

Conversely, the significance and effectiveness of both mass and targeted chemoprophylaxis in interrupting transmission of GAS varies within current literature. A 2012 UK paper, which investigated management of 20 iGAS outbreaks in UK aged care facilities, concluded that, based on the available data, there was no clear evidence that prophylactic chemoprophylaxis is an effective outbreak management tool. The authors conceded that more systematic data may be required to inform future policy. 8 Four years later, another UK RACF review attributed the introduction of mass chemoprophylaxis, in addition to improvement in infection control practices, as the likely reason for no further iGAS cases. 12 When managing an iGAS outbreak in a comparable metropolitan PHU in Queensland Australia in 2016, an expert advisory group recommended mass chemoprophylaxis within one wing of the facility and yet experienced an additional iGAS case within the same wing after the intervention, albeit one month later. 3 One report, of a 36-month outbreak in a RACF in the USA, identified mass chemoprophylaxis alone (and not in combination with remedying infection control inadequacies), as the intervention which finally interrupted transmission.14

Unlike mass chemoprophylaxis, in which all staff and residents within a facility (or subset of a facility) are prescribed antibiotics, ‘targeted’ or ‘selective’ chemoprophylaxis refers to screening for GAS carriage and only selectively treating those who return a positive GAS sample. One benefit of this approach is that implementation would likely be less challenging than experienced by the PHU. However, available evidence supporting effectiveness is not strong. In a 2019 New Zealand report, targeted chemoprophylaxis was implemented and was thought to have played a role in preventing some cases; yet, following a second phase, it was acknowledged that targeted chemoprophylaxis as a standalone approach was insufficient. Notably, mass chemoprophylaxis was not introduced even after this second phase. 10 When considering a targeted approach, it should be acknowledged that performing throat swabs and awaiting results may result in untimely delays prior to the commencement of chemoprophylaxis. The best available evidence suggests that the highest risk for iGAS transmission between household contacts is considered to be in the first seven days, and additionally, that antibiotics should be administered as soon as possible following exposure. 2 Even a 24–48 hour wait pending swab results could leave contacts at greater risk of invasive disease. Another point for consideration, not found in the cited literature, is that a targeted approach may adversely affect staff or residents who test positive for GAS. For example, a nurse who had attended wound care of a confirmed iGAS case may feel responsible for transmission if they are subsequently found to be positive for GAS carriage. This might be especially impactful if fatalities resulted from any presumed breach.

Though this outbreak was guided by traditional epidemiological links and by the use of strain emm typing, in more recent years published literature reveals an increased usage of whole genome sequencing (WGS) as an investigative tool in iGAS outbreaks. WGS has been shown to be more effective, more accurate, and faster for identifying emm gene types in GAS isolates than traditional emm typing. 15 A 2019 USA study cites WGS as a major factor in differentiating between intra-facility transmission (i.e. poor infection control) and introduction of other strains from the community. 9 In the previously-cited 2016 UK outbreak where no cases were reported after mass chemoprophylaxis, WGS was identified, in combination with epidemiological factors, as essential for triggering the timely response. 12 In the outbreak we have described here, emm typing results were not known for approximately a month. If these results were waited upon prior to escalating outbreak management, this may have negatively impacted ultimate control. Undoubtedly, the shorter turnaround times offered by WGS will play a key role in guiding both future iGAS outbreak detection and response including decisions regarding mass chemoprophylaxis.

While it is generally accepted that mass chemoprophylaxis is not intended to be a replacement for good infection control in halting iGAS outbreaks, the experiences of others documented in the literature suggest that more prolonged outbreaks can be associated with either no chemoprophylaxis or targeted chemoprophylaxis alone. Nonetheless, the current evidence is not conclusive on the role of mass chemoprophylaxis as an intervention for iGAS outbreaks. We have reported here a positive experience with mass chemoprophylaxis as one of the interventions contributing to control of an iGAS outbreak in a local RACF. However, as demonstrated, mass chemoprophylaxis can be a challenging undertaking. The decision to commence mass chemoprophylaxis should be, in conjunction with jurisdictional guidelines, reliant upon a thorough public health risk assessment, utilising available investigative tools, and on careful consideration of the unique characteristics of the outbreak.

# Author details

Jai C Van Zeeland 1   
Dr Heshani Rupasinghe 1,2   
Dr Megan K Young 1,3

1. Metro North Public Health Unit, Queensland Health.
2. Royal Australian College of Physicians Paediatrics & Child Health Division
3. School of Public Health, University of Queensland and School of Medicine, Griffith University

## Corresponding author

Jai Van Zeeland

Metro North Public Health Unit, Queensland Health, Rosemount Campus, Windsor, Qld 4350   
Phone: (07) 3624 1111   
Email: Jaivanzeeland@gmail.com

# References

1. Queensland Health. Invasive Group A Streptococcal Disease. [Internet.] Brisbane: Queensland Government, Queensland Health; 9 November 2018. [Accessed in January 2021.] Available from: https://www.health.qld.gov.au/cdcg/index/igas.
2. Northern Territory Government Department of Health. Public health management of invasive group A streptococcal infection. [Internet.] Darwin: Northern Territory Government, Health Library Services ePublications; November 2015. [Accessed in February 2022.] Available from: https://hdl.handle.net/10137/1187.
3. Vasant BR, Jarvinen KAJ, Fang NX, Smith HV, Jennison AV. Mass prophylaxis in an outbreak of invasive group A streptococcal disease in a residential aged care facility. Commun Dis Intell (2018) . 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.18.
4. Queensland Government: Queensland Legislation. Public Health Act 2005 . [Legislation.] Brisbane: Queensland Government, Queensland Legislation, 8 March 2021. [Accessed on 12 April 2021.] Available from: https://www.legislation.qld.gov.au/view/html/inforce/current/act-2005-048.
5. Gherardi G, Vitali LA, Creti R. Prevalent emm types among invasive GAS in Europe and North America since year 2000. Front Public Health . 2018;6:59. doi: https://doi.org/10.3389/fpubh.2018.00059.
6. Lee MH, Lee GA, Lee SH, Park YH. A systematic review on the causes of the transmission and control measures of outbreaks in long-term care facilities: back to basics of infection control. PLoS One . 2020;15(3):e0229911. doi: https://doi.org/10.1371/journal.pone.0229911.
7. Jordan HT, Richards CL, Burton DC, Thigpen MC, Van Beneden CA. Group A streptococcal disease in long-term care facilities: descriptive epidemiology and potential control measures. Clin Infect Dis . 2007;45(6):742–52. doi: https://doi.org/10.1086/520992.
8. Cummins A, Millership S, Lamagni T, Foster K. Control measures for invasive group A streptococci (iGAS) outbreaks in care homes. J Infect . 2012;64(2):156–61. doi: https://doi.org/10.1016/j.jinf.2011.11.017.
9. Nanduri SA, Metcalf BJ, Arwady MA, Edens C, Lavin MA, Morgan J et al. Prolonged and large outbreak of invasive group A streptococcus disease within a nursing home: repeated intrafacility transmission of a single strain. Clin Microbiol Infect . 2019;25(2):248.e1–7. doi: https://doi.org/10.1016/j.cmi.2018.04.034.
10. Worthing KA, Werno A, Pink R, McIntyre L, Carter GP, Williamson DA et al. Biphasic outbreak of invasive group A streptococcus disease in eldercare facility, New Zealand. Emerg Infect Dis . 2020;26(5):841–8. doi: https://doi.org/10.3201/eid2605.190131.
11. Centers for Disease Control and Prevention (CDC). Invasive group A streptococcus in a skilled nursing facility – Pennsylvania 2009–2010. MMWR Morb Mortal Wkly Rep . 2011;60(42):1445–9.
12. Chalker VJ, Smith A, Al-Shahib A, Botchway S, Macdonald E, Daniel R et al. Integration of genomic and other epidemiologic data to investigate and control a cross-institutional outbreak of Streptococcus pyogenes . Emerg Infect Dis . 2016;22(6):973–80. https://doi.org/10.3201/eid2206.142050.
13. Mearkle R, Saavedra-Campos M, Lamagni T, Usdin M, Coelho J, Chalker V et al. Household transmission of invasive group A streptococcus infections in England: a population-based study, 2009, 2011 to 2013. Euro Surveill . 2017;22(3):30532. doi: https://doi.org/10.2807/15607917.ES.2017.22.19.30532.
14. Dooling KL, Crist MB, Nguyen DB, Bass J, Lorentzson L, Toews KA et al. Investigation of a prolonged group A streptococcal outbreak among residents of a skilled nursing facility, Georgia, 2009–2012. Clin Infect Dis . 2013;57(11):1562–7. doi: https://doi.org/10.1093/cid/cit558.
15. Kapatai G, Coelho J, Platt S, Chalker VJ. Whole genome sequencing of group A Streptococcus : development and evaluation of an automated pipeline for emm gene typing. PeerJ . 2017;5:e3226. doi: https://doi.org/10.7717/peerj.3226.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection and Response, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Noel Lally

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection and Response, Australian Government Department of Health, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2022 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>